Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report) Director Peter Thompson sold 48,546 shares of the stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $44.61, for a total value of $2,165,637.06. Following the completion of the sale, the director directly owned 2,916,228 shares of the company’s […]

Astera Labs, Inc. (NASDAQ:ALAB – Get Free Report) COO Sanjay Gajendra sold 49,361 shares of Astera Labs stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $199.21, for a total transaction of $9,833,204.81. Following the completion of the sale, the chief operating officer owned 655,000 […]

Astera Labs, Inc. (NASDAQ:ALAB – Get Free Report) COO Sanjay Gajendra sold 230,639 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $198.22, for a total transaction of $45,717,262.58. Following the transaction, the chief operating officer owned 664,361 shares in the company, valued […]

Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report) CEO Christopher Kroeger sold 13,980 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $30.11, for a total transaction of $420,937.80. Following the completion of the sale, the chief executive officer owned 1,512,329 […]

Expensify, Inc. (NASDAQ:EXFY – Get Free Report) CEO David Michael Barrett sold 30,000 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $1.08, for a total transaction of $32,400.00. Following the completion of the sale, the chief executive officer directly owned 1,258,480 shares in […]

StoneX Group Inc. (NASDAQ:SNEX – Get Free Report) Director Eric Parthemore sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $123.30, for a total value of $308,250.00. Following the sale, the director owned 43,874 shares in the company, valued […]

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) Director Bryan Giraudo sold 36,000 shares of the business’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $100.14, for a total value of $3,605,040.00. Following the sale, the director owned 27,825 shares in the company, valued at approximately […]

Odyssey Therapeutics, Inc. (NASDAQ:ODTX – Get Free Report) Director Jeffrey Leiden acquired 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The shares were bought at an average cost of $20.00 per share, for a total transaction of $100,000.00. Following the acquisition, the director directly owned 270,198 shares in […]